Thyroid hormone deficiency during crucial stages of development causes congenital
hypothyroidism. This syndrome alters hypothalamic pathways involved in long-term
bodyweight regulation as ObRb-STAT3 leptin signaling pathway, which is
associated with metabolic syndrome. This study aimed to determine if thyroxine
treatment during pregnancy and lactation in hypothyroid mothers avoids, in the
congenital hypothyroid offspring, the alterations in metabolic programming
related to metabolic syndrome and the ObRb-STAT3 leptin signaling pathway in
hypothalamus. Twenty-four virgin female Wistar rats were divided into euthyroid,
hypothyroid, and hypothyroid with thyroxine treatment (20
μg/kg/day T4 since pregnancy until
lactation). The bodyweight and energy intake, insulin resistance, glucose
tolerance, metabolic and hormonal parameters were determined in offspring at 28
weeks after birth. Then, the rats were euthanized to obtain adipose tissue
reserves and hypothalamus to measure the expression of ObRb, STAT3, pSTAT3, and
SOCS3. Congenital hypothyroidism presented metabolic syndrome such as insulin
resistance, glucose tolerance, dyslipidemias, an increase in cardiovascular risk
(Castelli I males:166.67%, females: 173.56%; Castelli II males:
375.51%, females: 546.67%), and hypothalamic leptin resistance
(SOCS3, Males: 10.96%, females: 25.85%). Meanwhile, the
thyroxine treatment in the mothers during pregnancy and lactation prevents the
metabolic disturbance. In conclusion, thyroxine treatment during the critical
perinatal stage for metabolic programming prevents congenital
hypothyroidism-caused metabolic syndrome and hypothalamic leptin resistance.